A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction - Rao, S V; Kirsch, B; Bhatt, D L; PACIFIC AMI Investigators (Circulation, 2022)